Home / Resource Library / A Multi-Targeted Strategy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Real-World Outcomes of the ViPOR Regimen

A Multi-Targeted Strategy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Real-World Outcomes of the ViPOR Regimen

Real world study of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide for treatment of relapsed non-Hodgkin lymphomas.